Healthcare of patients with immunoglobulin A nephropathy through a retrospective observational study of Italian administrative data.

IF 0.4 Q4 HEALTH CARE SCIENCES & SERVICES
Global & Regional Health Technology Assessment Pub Date : 2025-05-15 eCollection Date: 2025-01-01 DOI:10.33393/grhta.2025.3397
Luigi Biancone, Gaetano La Manna, Letizia Dondi, Leonardo Dondi, Giulia Ronconi, Silvia Calabria, Irene Dell'Anno, Carlo Piccinni, Immacolata Esposito, Alice Addesi, Nello Martini
{"title":"Healthcare of patients with immunoglobulin A nephropathy through a retrospective observational study of Italian administrative data.","authors":"Luigi Biancone, Gaetano La Manna, Letizia Dondi, Leonardo Dondi, Giulia Ronconi, Silvia Calabria, Irene Dell'Anno, Carlo Piccinni, Immacolata Esposito, Alice Addesi, Nello Martini","doi":"10.33393/grhta.2025.3397","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Immunoglobulin A nephropathy (IgAN) is a rare disease poorly described in real-world settings. This observational retrospective study aimed to assess the direct healthcare burden of new IgAN patients on the Italian National Healthcare Service (SSN).</p><p><strong>Methods: </strong>From the Fondazione Ricerca e Salute's database (administrative healthcare data of ~5.5 million inhabitants/year), inpatients with new potential in-hospital biopsy-verified IgAN from 2016 to 2019 were identified. Dispensations of IgAN-recommended and other drugs, kidney replacement therapies (KRT), hospital and emergency department (ED) admissions, local outpatient specialist care, and related direct costs were assessed throughout a 3-year follow-up.</p><p><strong>Results: </strong>New IgAN patients (n = 292) were identified (incidence/year: 1.25/100 000 inhabitants); 64% of patients were male; the median age was 41 (27; 57) years. Annual consumption of most healthcare resources decreased from Year 1 to 3: from 90% to 84% of patients received ≥1 IgAN-recommended drug; from 100% (due to selection criteria) to 15% of patients underwent overnight hospitalizations; from 8% to 3% patients underwent day hospitalizations; from 31% to 21% patients underwent ≥1 ED access; from 87% to 85% patients received local outpatient specialist services. Of all patients, 2-4% were treated with KRT, and ~91% received other drugs. The per capita mean total annual cost was €7441 in Year 1 (hospitalizations accounting for 73% due to selection criteria), €3497 in Year 2, and €3243 in Year 3 (drugs accounting for 51%, mostly attributable to other drugs).</p><p><strong>Conclusion: </strong>This real-world study shows a substantial direct healthcare burden for new IgAN patients arising from IgAN-specific care and comorbidities.</p>","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"12 ","pages":"130-140"},"PeriodicalIF":0.4000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12080238/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global & Regional Health Technology Assessment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33393/grhta.2025.3397","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Immunoglobulin A nephropathy (IgAN) is a rare disease poorly described in real-world settings. This observational retrospective study aimed to assess the direct healthcare burden of new IgAN patients on the Italian National Healthcare Service (SSN).

Methods: From the Fondazione Ricerca e Salute's database (administrative healthcare data of ~5.5 million inhabitants/year), inpatients with new potential in-hospital biopsy-verified IgAN from 2016 to 2019 were identified. Dispensations of IgAN-recommended and other drugs, kidney replacement therapies (KRT), hospital and emergency department (ED) admissions, local outpatient specialist care, and related direct costs were assessed throughout a 3-year follow-up.

Results: New IgAN patients (n = 292) were identified (incidence/year: 1.25/100 000 inhabitants); 64% of patients were male; the median age was 41 (27; 57) years. Annual consumption of most healthcare resources decreased from Year 1 to 3: from 90% to 84% of patients received ≥1 IgAN-recommended drug; from 100% (due to selection criteria) to 15% of patients underwent overnight hospitalizations; from 8% to 3% patients underwent day hospitalizations; from 31% to 21% patients underwent ≥1 ED access; from 87% to 85% patients received local outpatient specialist services. Of all patients, 2-4% were treated with KRT, and ~91% received other drugs. The per capita mean total annual cost was €7441 in Year 1 (hospitalizations accounting for 73% due to selection criteria), €3497 in Year 2, and €3243 in Year 3 (drugs accounting for 51%, mostly attributable to other drugs).

Conclusion: This real-world study shows a substantial direct healthcare burden for new IgAN patients arising from IgAN-specific care and comorbidities.

免疫球蛋白A肾病患者的保健通过意大利行政数据的回顾性观察研究。
背景:免疫球蛋白A肾病(IgAN)是一种罕见的疾病,在现实世界中很少被描述。本观察性回顾性研究旨在评估新IgAN患者在意大利国家医疗保健服务(SSN)上的直接医疗负担。方法:从国家卫生基金会数据库(约550万居民/年的行政卫生保健数据)中,筛选出2016 - 2019年住院活检证实的新潜在IgAN患者。在为期3年的随访中,评估了igan推荐的药物和其他药物的配药、肾脏替代疗法(KRT)、医院和急诊科(ED)入院、当地门诊专科护理和相关的直接费用。结果:发现了新的IgAN患者(n = 292)(发病率/年:1.25/10万居民);64%的患者为男性;中位年龄41岁(27岁;57年。从第1年到第3年,大多数医疗资源的年消耗量下降:从90%到84%的患者接受≥1种igan推荐药物;100%(根据选择标准)至15%的患者接受过夜住院治疗;8%至3%的患者接受了日间住院治疗;从31%到21%的患者接受了≥1次ED通路;87%至85%的患者接受了当地门诊专科服务。在所有患者中,2-4%接受KRT治疗,约91%接受其他药物治疗。人均年平均总费用第一年为7441欧元(因选择标准住院费用占73%),第二年为3497欧元,第三年为3243欧元(药物费用占51%,主要为其他药物)。结论:这项现实世界的研究表明,由于IgAN特异性护理和合并症,新IgAN患者的直接医疗负担很大。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Global & Regional Health Technology Assessment
Global & Regional Health Technology Assessment HEALTH CARE SCIENCES & SERVICES-
CiteScore
0.80
自引率
20.00%
发文量
27
审稿时长
8 weeks
期刊介绍: Global & Regional Health Technology Assessment (GRHTA) is a peer-reviewed, open access journal which aims to promote health technology assessment and economic evaluation, enabling choices among alternative therapeutical paths or procedures with different clinical and economic outcomes. GRHTA is a unique journal having three different editorial boards who focus on their respective geographical expertise.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信